Dear user, the application need JavaScript support. Please enable JavaScript in your browser.

You are browsing as a GUEST
Title of the item:

Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine.

Title :
Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine.
Authors :
Dunkl, Veronika
Ceccon, Garry
Steger, Jan
Bauer, Elena K.
Tscherpel, Caroline
Fink, Gereon R.
Galldiks, Norbert
Stoffels, Gabriele
Lohmann, Philipp
Shah, Nadim J.
Langen, Karl-Josef
Law, Ian
Henriksen, Otto M.
Muhic, Aida
Poulsen, Hans S.
Schmidt, Matthias
Show more
Subject Terms :
GLIOMA treatment
MAGNETIC resonance imaging
POSITRON emission
CANCER invasiveness
Source :
European Journal of Nuclear Medicine & Molecular Imaging; Dec2018, Vol. 45 Issue 13, p2377-2386, 10p, 1 Diagram, 4 Charts, 2 Graphs
Academic Journal
Background: The goal of this prospective study was to compare the value of both conventional MRI and O-(2-18F-fluoroethyl)-L-tyrosine (FET) PET for response evaluation in glioblastoma patients treated with bevacizumab plus lomustine (BEV/LOM) at first progression.Methods: After chemoradiation with concomitant and adjuvant temozolomide, 21 IDH wild-type glioblastoma patients at first progression (age range, 33-75 years; MGMT promoter unmethylated, 81%) were treated with BEV/LOM. Contrast-enhanced MRI and FET-PET scans were performed at baseline and after 8-10 weeks. We obtained FET metabolic tumor volumes (MTV) and tumor/brain ratios. Threshold values of FET-PET parameters for treatment response were established by ROC analyses using the post-progression overall survival (OS) ≤/>9 months as the reference. MRI response assessment was based on RANO criteria. The predictive ability of FET-PET thresholds and MRI changes on early response assessment was evaluated subsequently concerning OS using uni- and multivariate survival estimates.Results: Early treatment response as assessed by RANO criteria was not predictive for an OS>9 months (P = 0.203), whereas relative reductions of all FET-PET parameters significantly predicted an OS>9 months (P < 0.05). The absolute MTV at follow-up enabled the most significant OS prediction (sensitivity, 85%; specificity, 88%; P = 0.001). Patients with an absolute MTV below 5 ml at follow-up survived significantly longer (12 vs. 6 months, P < 0.001), whereas early responders defined by RANO criteria lived only insignificantly longer (9 vs. 6 months; P = 0.072). The absolute MTV at follow-up remained significant in the multivariate survival analysis (P = 0.006).Conclusions: FET-PET appears to be useful for identifying responders to BEV/LOM early after treatment initiation. [ABSTRACT FROM AUTHOR]
Copyright of European Journal of Nuclear Medicine & Molecular Imaging is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Please log in to access the full text.

We use cookies to help identify your computer so we can tailor your user experience, track shopping basket contents and remember where you are in the order process.